Kairos Pharma, Ltd. (NYSE American: KAPA) announced a peer-reviewed publication in Drug Resistance Updates, highlighting a significant breakthrough in addressing drug resistance to EGFR-targeted therapies for non-small cell lung cancer (NSCLC) patients. The study revealed the critical role of CD105 (endoglin) in mediating resistance to osimertinib, a frontline treatment.
The publication, titled 'CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer,' demonstrated that CD105 expression is upregulated as a mechanism of therapy resistance, correlating with poor prognosis. In preclinical models, targeting CD105 with ENV105 (carotuximab) successfully restored treatment sensitivity to EGFR-targeted therapies.
Combining osimertinib with ENV105 reinstated susceptibility to EGFR inhibition through metabolic reprogramming and enhanced chromatin accessibility, confirming the efficacy of this novel combination therapy strategy. These findings corroborate data in prostate, breast, and colon cancer, pointing to CD105 as a central mechanism of cancer drug resistance and positioning ENV105 as a high-value asset in next-generation oncology treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.